NCT00710528已完成1 期
A Phase 1 Sequential Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of CAL-101 in Patients With Select, Relapsed or Refractory Hematologic Malignancies
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 192
- 试验地点
- 9
- 主要终点
- To evaluate the safety of CAL-101 and determine the dose limiting toxicity in patients with hematologic malignancies.
研究概览
简要总结
The purpose of this study is to determine the dose that can be safely given to see what effect it may have on your cancer and to determine how the drug is distributed in the body.
详细描述
A Phase 1, sequential dose escalation followed by cohort expansion study of CAL-101, an oral inhibitor of PI3K delta, in patients with relapsed or refractory CLL, select B-cell NHL and AML.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age > or =
- •Has relapsed or refractory disease as defined by the following:
- •CLL - refractory to or relapsed after at least 2 prior therapies, including fludarabine, alone or in combination. Patients should not be eligible for transplantation (patients who are candidates for transplantation and have declined transplantation are eligible for this study).
- •B-cell NHL - refractory to or relapsed after at least 1 prior chemotherapy regimen and having received rituximab as a single agent or in combination with other therapies.
- •AML - refractory to or relapsed after at least 1 cycle of induction chemotherapy. Patients over the age of 70 who are not appropriate candidates for chemotherapy are eligible for this study.
- •MM - refractory to or relapsed after at least 2 prior chemotherapy regimens, including bortezomib and thalidomide or lenalidomide (except if the drug is contraindicated in a patient then this requirement is waived).
- •Disease status requirement:
- •For CLL patients, symptomatic disease that mandate treatment.
- •For B-cell NHL patients, has measurable disease by CT scan.
- •For AML patients, has > 10% blasts in the bone marrow for refractory or relapsed disease and > 20% blasts in the bone marrow if no prior chemotherapy.
- •For MM patients, has measurable disease defined by at least 1 of the following 3 measurements: serum M-protein > or = to 1 g/dL, urine M-protein > or = to 200 mg/24 h, or serum free light chain (FLC) assay with involved FLC level > or = to 10 mg/dL provided serum FLC ratio is abnormal.
- •WHO performance status of ≤
- •For men and women of child-bearing potential, willing to use adequate contraception (i.e., latex condom, cervical cap, diaphragm, abstinence, etc.) for the entire duration of the study.
- •Is able to provide written informed consent.
排除标准
- •Had radiotherapy, radioimmunotherapy, biological therapy, chemotherapy, or treatment with an investigational product within 4-weeks prior to screening.
- •For CLL or NHL patients, had treatment with a short course of corticosteroids for symptom relief within 1-week prior to screening.
- •Had alemtuzumab therapy within 12-weeks prior to screening.
- •For AML patients, had treatment with hydroxyurea within 1-week prior to screening.
- •Is pregnant or nursing.
- •Has significant, ongoing co-morbid conditions which would preclude safe delivery of the study drug.
- •Has had a transplant with current active graft-versus-host-disease.
- •Has known active central nervous system involvement of the malignancy.
- •Has active, serious infection requiring systemic therapy. Patients may receive prophylactic antibiotics and antiviral therapy at the discretion of the treating physician.
- •Has significant renal or liver dysfunction.
- •Has severe thrombocytopenia requiring platelet transfusion support, unless the diagnosis is AML.
- •Has a positive test for human immunodeficiency virus (HIV) antibodies.
- •Has active hepatitis B or C. Patients with serologic evidence of prior exposure are eligible.
- •Has poorly controlled diabetes mellitus.
- •Has taken a medication that is a potent inhibitor or inducer of cytochrome P450 3A4 within 1-week prior to screening.
研究组 & 干预措施
one arm
Experimental
干预措施: CAL-101 (Drug)
结局指标
主要结局
To evaluate the safety of CAL-101 and determine the dose limiting toxicity in patients with hematologic malignancies.
时间窗: 28 days
次要结局
- To evaluate the pharmacokinetic parameters, pharmacodynamic effects and clinical response rate following CAL-101 treatment in patients with hematologic malignancies.(28 Days)
研究者
研究点 (9)
Loading locations...
相似试验
已完成
1 期
SAP Depleter Dose Escalation Study in Healthy VolunteersAmyloidosisNCT01323985GlaxoSmithKline21
已完成
1 期
Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian CancerFallopian Tube CancerPrimary Peritoneal CancerEpithelial Ovarian CancerNCT02480374Imunon18
已完成
1 期
A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)Carcinoma, Renal CellNCT04846920Merck Sharp & Dohme LLC29
已完成
1 期
BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal MalignanciesColorectal CancerNCT00207051Bristol-Myers Squibb62
终止
1 期
A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological MalignanciesLymphoid Hematological MalignanciesRelapsed and Refractory Multiple MyelomaNCT02223598Cleave Biosciences, Inc.120